Hardens M
AIDS. 1996 Dec;10 Suppl 4:S25-30.
To describe the treatment patterns for intravenous ganciclovir induction and maintenance therapy in AIDS patients with cytomegalovirus (CMV) retinitis in five European countries and to investigate the anticipated impact of oral ganciclovir on resource utilization during maintenance.
Study was a retrospective analysis based on a prospective randomized clinical trial (AV1034) comparing the efficacy of oral versus intravenous ganciclovir in CMV retinitis maintenance therapy. Resource utilization patterns for ganciclovir induction and maintenance, retinitis progression and management and treatment of adverse events were based on clinical trial data and interviews with local experts involved in treatment of patients with CMV retinitis.
Oral ganciclovir maintenance was effective, although associated with a faster time to progression, compared to intravenous ganciclovir. There was considerable variation in the treatment patterns for induction with intravenous ganciclovir in the different countries. Most inductions were achieved with a central intravenous line, also used in subsequent intravenous maintenance therapy, usually performed on an outpatient or day care inpatient basis. Intravenous maintenance therapy was identified as a large resource utilization which would decrease considerably with the introduction of oral ganciclovir. In addition, decreased incidence of adverse side effects with oral ganciclovir would also lead to decreased resource use.
Introduction of oral ganciclovir is expected to lead to significant reduction in resource use and may avoid the need for central line placement. This, and the lower incidence of adverse side effects, normally associated with intravenous ganciclovir, are also expected to lead to improvement in the patient's quality of life.
描述欧洲五个国家艾滋病合并巨细胞病毒(CMV)视网膜炎患者静脉注射更昔洛韦诱导和维持治疗的模式,并调查口服更昔洛韦对维持治疗期间资源利用的预期影响。
该研究是基于一项前瞻性随机临床试验(AV1034)的回顾性分析,该试验比较了口服与静脉注射更昔洛韦在CMV视网膜炎维持治疗中的疗效。更昔洛韦诱导和维持、视网膜炎进展及管理以及不良事件治疗的资源利用模式基于临床试验数据以及对参与CMV视网膜炎患者治疗的当地专家的访谈。
与静脉注射更昔洛韦相比,口服更昔洛韦维持治疗有效,尽管疾病进展时间更快。不同国家静脉注射更昔洛韦诱导治疗模式存在相当大的差异。大多数诱导治疗通过中心静脉导管进行,后续静脉维持治疗也使用该导管,通常在门诊或日间护理住院基础上进行。静脉维持治疗被确定为资源利用大户,随着口服更昔洛韦的引入,其使用将大幅减少。此外,口服更昔洛韦不良副作用发生率降低也将导致资源使用减少。
口服更昔洛韦的引入预计将显著减少资源使用,并可能避免中心静脉导管置管的需要。这一点以及通常与静脉注射更昔洛韦相关的较低不良副作用发生率,预计也将改善患者的生活质量。